Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/24192252/ below:

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

Comparative Study

Collaborators, Affiliations

• International HPV screening working group: Jack Cuzick, Marco Zappa, Francesca Carozzi, Massimo Confortini, Paolo Dalla Palma, Manuel Zorzi, Annarosa Del Mistro, Anna Gillio-Tos, Carlo Naldoni, Dorien Rijkaart, Folkert van Kemenade, Nicole Bulkmans, Danielle Heideman, Rence Rozendaal, Gemma Kenter, Maribel Almonte, Christopher Roberts, Mina Desai, Alexandra Sargent, Walter Ryd, Pontus Naucler

• ¹ Center for Cancer Epidemiology and Prevention, AO City of Health and Science, Turin, Italy. Electronic address: guglielmo.ronco@cpo.it.
• ² Karolinska Institutet, Stockholm, Sweden.
• ³ Center for Cancer Epidemiology and Prevention, AO City of Health and Science, Turin, Italy.
• ⁴ VU University Medical Centre, Amsterdam, Netherlands.
• ⁵ Scientific Institute of Public Health, Brussels, Belgium.
• ⁶ Institute of Cancer Sciences, University of Manchester, Manchester, UK.
• ⁷ Center for Cancer Epidemiology and Prevention, AO City of Health and Science, Turin, Italy; International Agency for Research on Cancer (IARC), Lyon, France.
• ⁸ London School of Hygiene and Tropical Medicine, London, UK.
• ⁹ Azienda Sanitaria Locale, Reggio Emilia, Italy.

• PMID: 24192252
• DOI: 10.1016/S0140-6736(13)62218-7

Item in Clipboard

Comparative Study

Guglielmo Ronco et al. Lancet. 2014.

• International HPV screening working group: Jack Cuzick, Marco Zappa, Francesca Carozzi, Massimo Confortini, Paolo Dalla Palma, Manuel Zorzi, Annarosa Del Mistro, Anna Gillio-Tos, Carlo Naldoni, Dorien Rijkaart, Folkert van Kemenade, Nicole Bulkmans, Danielle Heideman, Rence Rozendaal, Gemma Kenter, Maribel Almonte, Christopher Roberts, Mina Desai, Alexandra Sargent, Walter Ryd, Pontus Naucler

• ¹ Center for Cancer Epidemiology and Prevention, AO City of Health and Science, Turin, Italy. Electronic address: guglielmo.ronco@cpo.it.
• ² Karolinska Institutet, Stockholm, Sweden.
• ³ Center for Cancer Epidemiology and Prevention, AO City of Health and Science, Turin, Italy.
• ⁴ VU University Medical Centre, Amsterdam, Netherlands.
• ⁵ Scientific Institute of Public Health, Brussels, Belgium.
• ⁶ Institute of Cancer Sciences, University of Manchester, Manchester, UK.
• ⁷ Center for Cancer Epidemiology and Prevention, AO City of Health and Science, Turin, Italy; International Agency for Research on Cancer (IARC), Lyon, France.
• ⁸ London School of Hygiene and Tropical Medicine, London, UK.
• ⁹ Azienda Sanitaria Locale, Reggio Emilia, Italy.

• PMID: 24192252
• DOI: 10.1016/S0140-6736(13)62218-7

Item in Clipboard

• Department of Error.

  [No authors listed] [No authors listed] Lancet. 2015 Oct 10;386(10002):1446. doi: 10.1016/S0140-6736(15)00411-0. Lancet. 2015. PMID: 26466047 No abstract available.

Background: In four randomised trials, human papillomavirus (HPV)-based screening for cervical cancer was compared with cytology-based cervical screening, and precursors of cancer were the endpoint in every trial. However, direct estimates are missing of the relative efficacy of HPV-based versus cytology-based screening for prevention of invasive cancer in women who undergo regular screening, of modifiers (eg, age) of this relative efficacy, and of the duration of protection. We did a follow-up study of the four randomised trials to investigate these outcomes.

Methods: 176,464 women aged 20-64 years were randomly assigned to HPV-based (experimental arm) or cytology-based (control arm) screening in Sweden (Swedescreen), the Netherlands (POBASCAM), England (ARTISTIC), and Italy (NTCC). We followed up these women for a median of 6·5 years (1,214,415 person-years) and identified 107 invasive cervical carcinomas by linkage with screening, pathology, and cancer registries, by masked review of histological specimens, or from reports. Cumulative and study-adjusted rate ratios (experimental vs control) were calculated for incidence of invasive cervical carcinoma.

Findings: The rate ratio for invasive cervical carcinoma among all women from recruitment to end of follow-up was 0·60 (95% CI 0·40-0·89), with no heterogeneity between studies (p=0·52). Detection of invasive cervical carcinoma was similar between screening methods during the first 2·5 years of follow-up (0·79, 0·46-1·36) but was significantly lower in the experimental arm thereafter (0·45, 0·25-0·81). In women with a negative screening test at entry, the rate ratio was 0·30 (0·15-0·60). The cumulative incidence of invasive cervical carcinoma in women with negative entry tests was 4·6 per 10(5) (1·1-12·1) and 8·7 per 10(5) (3·3-18·6) at 3·5 and 5·5 years, respectively, in the experimental arm, and 15·4 per 10(5) (7·9-27·0) and 36·0 per 10(5) (23·2-53·5), respectively, in the control arm. Rate ratios did not differ by cancer stage, but were lower for adenocarcinoma (0·31, 0·14-0·69) than for squamous-cell carcinoma (0·78, 0·49-1·25). The rate ratio was lowest in women aged 30-34 years (0·36, 0·14-0·94).

Interpretation: HPV-based screening provides 60-70% greater protection against invasive cervical carcinomas compared with cytology. Data of large-scale randomised trials support initiation of HPV-based screening from age 30 years and extension of screening intervals to at least 5 years.

Funding: European Union, Belgian Foundation Against Cancer, KCE-Centre d'Expertise, IARC, The Netherlands Organisation for Health Research and Development, the Italian Ministry of Health.

Copyright © 2014 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

• Embracing a new era in cervical cancer screening.

  Isidean SD, Franco EL. Isidean SD, et al. Lancet. 2014 Feb 8;383(9916):493-4. doi: 10.1016/S0140-6736(13)62028-0. Epub 2013 Nov 3. Lancet. 2014. PMID: 24192251 No abstract available.

• Combined HPV and cytology better than cytology for protection against cervical cancer.

  Ruffin M. Ruffin M. Evid Based Med. 2014 Aug;19(4):148. doi: 10.1136/eb-2014-101792. Epub 2014 Apr 2. Evid Based Med. 2014. PMID: 24694516 No abstract available.

• HPV-based screening for prevention of invasive cervical cancer.

  Sideri M, Igidbashian S. Sideri M, et al. Lancet. 2014 Apr 12;383(9925):1294. doi: 10.1016/S0140-6736(14)60643-7. Lancet. 2014. PMID: 24725574 No abstract available.

• HPV-based screening for prevention of invasive cervical cancer.

  Schneider A, Petry U, Erdemoglu E, Paavonen J. Schneider A, et al. Lancet. 2014 Apr 12;383(9925):1294-1295. doi: 10.1016/S0140-6736(14)60644-9. Lancet. 2014. PMID: 24725575 No abstract available.

• HPV-based screening for prevention of invasive cervical cancer - Authors' reply.

  Ronco G, Meijer CJL, Segnan N, Kitchener H, Giorgi-Rossi P, Peto J, Dillner J. Ronco G, et al. Lancet. 2014 Apr 12;383(9925):1295. doi: 10.1016/S0140-6736(14)60645-0. Lancet. 2014. PMID: 24725577 No abstract available.

• HPV testing for cervical cancer screening: time for a new paradigm.

  Lata K, Bhatla N. Lata K, et al. Natl Med J India. 2014 Jul-Aug;27(4):212-3. Natl Med J India. 2014. PMID: 25668167 No abstract available.

• The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

  C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J. C Kitchener H, et al. Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230. Health Technol Assess. 2014. PMID: 24762804 Free PMC article. Clinical Trial.

• [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].

  Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P. Ronco G, et al. Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Epidemiol Prev. 2012. PMID: 22828243 Italian.

• [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].

  Ronco G, Confortini M, Maccallini V, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Giorgi Rossi P. Ronco G, et al. Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 2):e1-e33. Epidemiol Prev. 2012. PMID: 23139163 Review. Italian.

• HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.

  Gilham C, Sargent A, Kitchener HC, Peto J. Gilham C, et al. Health Technol Assess. 2019 Jun;23(28):1-44. doi: 10.3310/hta23280. Health Technol Assess. 2019. PMID: 31219027 Free PMC article. Clinical Trial.

• Cytology versus HPV testing for cervical cancer screening in the general population.

  Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, Schünemann H, Paraskevaidis E, Arbyn M. Koliopoulos G, et al. Cochrane Database Syst Rev. 2017 Aug 10;8(8):CD008587. doi: 10.1002/14651858.CD008587.pub2. Cochrane Database Syst Rev. 2017. PMID: 28796882 Free PMC article. Review.

• Urine HPV in the Context of Genital and Cervical Cancer Screening-An Update of Current Literature.

  Daponte A, Michail G, Daponte AI, Daponte N, Valasoulis G. Daponte A, et al. Cancers (Basel). 2021 Apr 1;13(7):1640. doi: 10.3390/cancers13071640. Cancers (Basel). 2021. PMID: 33915878 Free PMC article. Review.

• Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China.

  Xu H, Lin A, Shao X, Shi W, Zhang Y, Yan W. Xu H, et al. Oncotarget. 2016 Dec 13;7(50):83775-83783. doi: 10.18632/oncotarget.11959. Oncotarget. 2016. PMID: 27626178 Free PMC article.

• Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.

  Dhillon SK, Oštrbenk Valenčak A, Xu L, Poljak M, Arbyn M. Dhillon SK, et al. J Clin Microbiol. 2021 May 19;59(6):e00286-21. doi: 10.1128/JCM.00286-21. Print 2021 May 19. J Clin Microbiol. 2021. PMID: 33731413 Free PMC article.

• Long-term protection of HPV test in women at risk of cervical cancer.

  Ibáñez R, Roura E, Monfil L, Rodríguez LA, Sardà M, Crespo N, Pascual A, Martí C, Fibla M, Gutiérrez C, Lloveras B, Oliveras G, Torrent A, Català I, Bosch FX, Bruni L, de Sanjosé S. Ibáñez R, et al. PLoS One. 2020 Aug 27;15(8):e0237988. doi: 10.1371/journal.pone.0237988. eCollection 2020. PLoS One. 2020. PMID: 32853216 Free PMC article.

• Evaluation of triage strategies for high-risk human papillomavirus-positive women in cervical cancer screening: A multicenter randomized controlled trial in different resource settings in China.

  Dang L, Kong L, Zhao Y, Dai Y, Ma L, Wei L, Zhang S, Liu J, Xi M, Chen L, Duan X, Xiao Q, Abulizi G, Zhang G, Hong Y, Zhou Q, Xie X, Li L, Niyazi M, Zhang Z, Tuo J, Ding Y, Qiao Y, Lang J. Dang L, et al. Chin J Cancer Res. 2022 Oct 30;34(5):496-509. doi: 10.21147/j.issn.1000-9604.2022.05.09. Chin J Cancer Res. 2022. PMID: 36398123 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3